Today, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with the implementation of nanoparticles for disease prevention, diagnosis, therapy and follow-up. Nanoparticles or nanocontainers offer advantages including high sensitivity, lower toxicity and improved safety-characteristics that are especially valued in the oncology field. Cancer cells develop and proliferate in complex microenvironments leading to heterogeneous diseases, often with a fatal outcome for the patient. Although antibody-based therapy is widely used in the clinical care of patients with solid tumours, its efficiency definitely needs improvement. Limitations of antibodies result mainly from their big size and poor penetration in solid tissues. Nanobodies are a novel and unique class of antigen-binding fragments, derived from naturally occurring heavy-chain-only antibodies present in the serum of camelids. Their superior properties such as small size, high stability, strong antigen-binding affinity, water solubility and natural origin make them suitable for development into next-generation biodrugs. Less than 30 years after the discovery of functional heavy-chain-only antibodies, the nanobody derivatives are already extensively used by the biotechnology research community. Moreover, a number of nanobodies are under clinical investigation for a wide spectrum of human diseases including inflammation, breast cancer, brain tumours, lung diseases and infectious diseases. Recently, caplacizumab, a bivalent nanobody, received approval from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for treatment of patients with thrombotic thrombocytopenic purpura.
Conflict of interest statement
Ivana Jovčevska and Serge Muyldermans declare they have no conflict of interest.
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.Front Immunol. 2017 Nov 22;8:1603. doi: 10.3389/fimmu.2017.01603. eCollection 2017. Front Immunol. 2017. PMID: 29213270 Free PMC article. Review.
[99mTc]Epidermal growth factor receptor–specific nanobody.2008 Apr 22 [updated 2008 May 13]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. Molecular Imaging and Contrast Agent Database (MICAD). 2004–2013. PMID: 20641885 Free Books & Documents. Review.
Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer.Antibodies (Basel). 2019 Jan 21;8(1):13. doi: 10.3390/antib8010013. Antibodies (Basel). 2019. PMID: 31544819 Free PMC article. Review.
Nanobodies in Human Infections: Prevention, Detection, and Treatment.Immunol Invest. 2019 Dec 19:1-22. doi: 10.1080/08820139.2019.1688828. Online ahead of print. Immunol Invest. 2019. PMID: 31856615
Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.Cancer Immunol Immunother. 2007 Mar;56(3):303-317. doi: 10.1007/s00262-006-0180-4. Cancer Immunol Immunother. 2007. PMID: 16738850
Cited by 1 article
Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?Pharmaceutics. 2020 Jan 13;12(1):62. doi: 10.3390/pharmaceutics12010062. Pharmaceutics. 2020. PMID: 31940974 Free PMC article. Review.